Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node-negative patients

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 1117-1125

  Gasparini, Giampietro ^a   Toi, Masakazu ^b   Verderio, Paolo ^c   Ranieri, Girolamo ^a   Dante, Stefania ^d   Bonoldi, Emanuela ^d   Boracchi, Patrizia ^c   Fanelli, Massimo ^a   Tominaga, Takeshi ^b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c UNIVERSITY OF MILAN   (Italy)

^d St Bortolo Regional Medical Center   (Italy)

Author keywords

Adjuvant treatments; Angiogenesis; Breast cancer; Hormone receptors; Nodal status; p53; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MENOPAUSE; MICROCIRCULATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; SURVIVAL RATE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031976472     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.5.1117     Document Type: Article

References (38)

1. Gasparini G: Quantification of intratumoral vascularisation predict metastasis in human invasive solid tumors (Review). Oncol Rep 1: 7-12, 1994.
2. Weidner N: Intratumoral microvessel density as a prognostic factor in cancer (Commentary). Am J Pathol 147: 1-11, 1995.
3. Gasparini G and Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 13: 765-782, 1995.
4. Ellis LM and Fidler IJ: Angiogenesis and breast cancer metastasis. Lancet 346: 388-390, 1995.
5. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M and Harris AL: Tumor angiogenesis in node-negative breast carcinomas - relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29: 109-116, 1994.
6. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E and Pozza F: Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454-466, 1994.
7. Obermair A, Kurz C, Czerwenka K, Tholma M, Kaider A, Wagner T, Gitsch G and Sevelda P: Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer 62: 126-131, 1995.
8. Inada K, Toi M, Hoshina S, Hayashi K and Tominaga T: Significance of tumor angiogenesis as an independent prognostic factor in axillary node-negative breast cancer. Gan To Kagaku Ryoho 22 (Suppl. 1): 59-65, 1995.
9. Gasparini G, Barbareschi M, Boracchi P, Verdcrio P, Caffo O, Meli S, Dalla Palma P, Marubini E and Bevilacqua P: Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer J Sci Am 1: 131-141, 1995.
10. Macaulay VM, Fox SB, Zhang H, Whitehouse RM, Leek RD, Gatter KC, Bicknell R and Harris AL: Breast cancer angiogenesis and tamoxifen resistance. Endocr Rel Cancer 2: 97-103, 1995.
11. Gasparini G: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma (letter). J Natl Cancer Inst 87: 1799-1801, 1995.
12. Gasparini G: Is determination of angiogenesis activity in human tumours clinically useful? Eur J Cancer (In press).
13. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene (Review article). Nature 351: 453-456, 1991.
14. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R and deary K: Mutations in the p53 gene occur in diverse human tumor types. Nature 34: 705-708, 1989.
15. Chang F, Syrjanen S and Syrjanen K: Implications of the p53 tumor suppressor gene in clinical oncology. J Clin Oncol 13: 1009-1022, 1995.
16. Bergh J, Norberg T, Sjorgen S, Lindgren A and Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029-1034, 1995.
17. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE and Robert N: Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil and prednisone for breast cancer. J Natl Cancer Inst 82: 1254-1256, 1995.
18. Gasparini G: p53 and angiogenesis (letter). J Clin Oncol 13: 1829-1830, 1995.
19. Dameron KM, Volpert OV, Tainsky MA and Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1585, 1994.
20. Volpert OV, Stellmach V and Bouck N: The modulation of thrombospondin and other naturally occuring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 36: 119-126, 1995.
21. Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, Gallus G, Greco M, Luini A, Marubini E, Muscolino G, Rilke F, Salvadori B, Zecchini A and Zucali R: Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. N Engl J Med 305: 6-11, 1981.
22. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F and Sommers SC: The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol n. 4). Cancer 36: 1-85, 1975.
23. Bloom HG and Richardson WW: Histological grading and prognosis. Br J Cancer 11: 359-377, 1957.
24. Cox DR: Regression models and life table (with discussion). J Roy Statist Soc SerB Metho 34: 187-220, 1973.
25. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K and Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992.
26. Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla Palma P, Meli S, Weidner N and Gasparini G: Prognostic value of intratumoral-microvessel density, a measure of tumor angiogenesis, in node-negative breast cancer carcinoma - results of a multiparametric study. Breast Cancer Res Treat 36: 205-217, 1995.
27. Folkman J: Tumor angiogenesis in women with node-positive breast cancer (Commentary). Cancer J Sci Am 1: 106-108, 1995.
28. Gasparini G: Biological and clinical role of angiogenesis in breast cancer. Breast Cancer Res Treat 36: 103-107, 1995.
29. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher De, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
30. . Zaztawny RL, Salvino R, Chen J, Benchimol S and Ling V: The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8: 1529-1535, 1993.
31. Fritsche M, Haessler C and Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318, 1993.
32. Seshardi R, Leong AS-Y, McCaul K, Firgaira FA, Setlur V and Horsfall DJ: Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer patients. Int J Cancer (Pred Oncol) 69: 135-141, 1996.
33. Sjorgen S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L and Bergh J: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173-182, 1996.
34. Kovach JS, Hartmann A, Blaszyck H, Cunningham J, Schaid D and Sommer SS: Mutation detection by higher sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 93: 1093-1096, 1996.
35. . Elledge RM: Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? J Natl Cancer Inst 88: 141-143, 1996.
36. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 1992.
37. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E and Wittliff J: Influence of tumor estrogen and progesterone levels on the response of tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1: 227-241, 1983.
38. Clark GM, McGuire WL, Hubay CA, Person OH and Marshall JS: Progesterone receptor as a prognostic factor in stage II breast cancer. N Engl J Med 309: 1343-1347, 1983.